Article Image
IPFS News Link • Drugs and Medications

Prof Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients

• Paul Craig Roberts

Professor Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients

Posted on April 9, 2020

by covexit

The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.

Key findings are:

•No cardiac toxicity was observed.

•A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).

A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.

The authors conclude that:

"The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases."

See the complete abstract below.

The original abstract can be accessed here.

Also, the researchers made this table available.

It's not clear when the complete study will be made available.

ABSTRACT

Background

In a recent survey, most physicians worldwide considered that hydroxychloroquine (HCQ) and azithromycin (AZ) are the two most effective drugs among available molecules against COVID-19. Nevertheless, to date, one preliminary clinical trial only has demonstrated its efficacy on the viral load. Additionally, a clinical study including 80 patients was published, and in vitro efficiency of this association was demonstrated.


Purse.IO Save on All Amazon Purchases